Nurix Therapeutics, Inc. Common stock (NRIX) Stock
Key stats
- Market cap
- $1.78B
- Price / Earnings ratio
- 5.9x
- EPS (TTM)
- $2.50
- Volume
- Loading
- 52-week high
- $28.23
- 52-week low
- $12.01
Source: third-party data provider, as of November 13, 2026
Compare with NRIX
Recent news

NRIX Stock Clocks Worst Day Ever After Sanofi Discontinues Trial Of Licensed Drug: Wells Fargo Slashes Price Target
NRIX Stock Clocks Worst Day Ever After Sanofi Discontinues Trial Of Licensed Drug: Wells Fargo Slashes Price Target
NRIX

NRIX Slumps 35% After-Hours — What’s Driving The Selloff?
NRIX Slumps 35% After-Hours — What’s Driving The Selloff?
NRIX

Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates
Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates
NRIX

Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
NRIX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 28.56
- MACD 12/26/9
- -2.23
- EMA 9 of MACD
- -1.14
- MACD histogram
- -1.09
- SMA 50
- $23.67
- Price below SMA 50
- EMA 50
- $22.86
- Price below EMA 50
- SMA 200
- $20.15
- Price below SMA 200
- EMA 200
- $20.57
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

NRIX Stock Clocks Worst Day Ever After Sanofi Discontinues Trial Of Licensed Drug: Wells Fargo Slashes Price Target
NRIX Stock Clocks Worst Day Ever After Sanofi Discontinues Trial Of Licensed Drug: Wells Fargo Slashes Price Target
NRIX

NRIX Slumps 35% After-Hours — What’s Driving The Selloff?
NRIX Slumps 35% After-Hours — What’s Driving The Selloff?
NRIX

Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates
Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates
NRIX

Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
NRIX

Here's Why You Should Add NRIX Stock to Your Portfolio Now
Here's Why You Should Add NRIX Stock to Your Portfolio Now
NRIX

Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why
Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why
NRIX

Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep Momentum
Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep Momentum
NRIX

RHHBY's Gazyva Gets FDA Priority Review for Label Expansion
RHHBY's Gazyva Gets FDA Priority Review for Label Expansion
NRIX

Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
NRIX

Earnings Preview: Nurix Therapeutics, Inc. (NRIX) Q2 Earnings Expected to Decline
Earnings Preview: Nurix Therapeutics, Inc. (NRIX) Q2 Earnings Expected to Decline
NRIX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Nurix Therapeutics, Inc. Common stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Arthur T. Sands M.D., Ph.D. | CEO, President & Director | 1962 |
| Mr. Johannes Van Houte | Chief Financial Officer | 1967 |
| Dr. Gwenn M. Hansen Ph.D. | Chief Scientific Officer | 1971 |
| Dr. Christine Ring J.D., Ph.D. | Chief Legal Officer, Secretary & Chief Compliance Officer | 1965 |
| Dr. John Kuriyan Ph.D. | Founder & Member of Scientific Advisory Board | — |
| Dr. Arthur Weiss M.D., Ph.D. | Founder & Member of Scientific Advisory Board | — |
| Rita Kwong | Senior Accounting Manager | — |
| Dr. Pasit Phiasivongsa Ph.D. | Chief Technical Officer | — |
| Mr. Wesley Burwell | Chief Human Resources Officer | — |
| Dr. Jason Kantor Ph.D. | Chief Business Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 28.56
- MACD 12/26/9
- -2.23
- EMA 9 of MACD
- -1.14
- MACD histogram
- -1.09
- SMA 50
- $23.67
- Price below SMA 50
- EMA 50
- $22.86
- Price below EMA 50
- SMA 200
- $20.15
- Price below SMA 200
- EMA 200
- $20.57
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $20.00
- Average
- $32.29
- High
- $36.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -15.0 | +1.9 | ||||||||||
| 2022 | -37.2 | -14.7 | -9.8 | -20.6 | -15.6 | +32.8 | +19.8 | +2.1 | -20.5 | -2.9 | -6.1 | -9.9 |
| 2023 | +13.3 | -23.7 | -3.2 | +8.7 | +2.2 | -1.8 | -3.5 | -10.5 | -9.1 | -22.7 | +9.9 | +49.3 |
| 2024 | -22.7 | +51.5 | +8.4 | -17.6 | +20.4 | +30.0 | +4.6 | +17.4 | -9.6 | +11.3 | -9.6 | -12.3 |
| 2025 | +1.0 | -18.5 | -16.3 | +10.1 | -4.7 | -6.2 | -3.8 | -15.4 | +1.4 | +37.7 | +40.1 | +12.2 |
| 2026 | -8.5 | -6.6 | -2.0 | +7.9 | +5.7 | +39.5 | -2.9 | +11.0 | -8.9 | +14.8 | -36.5 |



